Literature DB >> 21817952

Evolution of laboratory values in patients with Kawasaki disease.

Adriana H Tremoulet1, Sonia Jain, Divya Chandrasekar, Xiaoying Sun, Yuichiro Sato, Jane C Burns.   

Abstract

BACKGROUND: As outlined in the 2004 American Heart Association guidelines, the diagnosis of Kawasaki disease (KD) is supported by results of clinical laboratory studies. However, detailed information regarding the evolution of these results during illness has not been previously reported. The goals of this project were to characterize the evolution of clinical laboratory values in KD before and after treatment with intravenous immunoglobulin (IVIG).
METHODS: Laboratory values from 380 unselected, consecutive KD patients were analyzed at 3 times: acute (illness day, 2-10; illness day 1 = first day of fever and before IVIG), subacute (illness day, 11-21), and convalescent (illness day, 22-60). Results were stratified by IVIG response and coronary artery outcome.
RESULTS: Although white blood cell count, percentage bands, erythrocyte sedimentation rate, and C-reactive protein values were highest and age-adjusted hemoglobin was lowest in the acute phase before IVIG, platelet count was highest in the subacute phase, and percentage lymphocytes and eosinophils were highest in the convalescent phase after IVIG. KD patients with coronary artery aneurysms had a higher white blood cell count in the subacute phase and higher erythrocyte sedimentation rate in the subacute and convalescent phases compared with those with dilated or normal coronary arteries.
CONCLUSIONS: A consistent evolution of laboratory values is associated with KD before and after treatment. Understanding the dynamic changes in laboratory values can assist physicians in using laboratory criteria to diagnose KD following the American Heart Association guidelines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21817952      PMCID: PMC3222731          DOI: 10.1097/INF.0b013e31822d4f56

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  20 in total

1.  Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.

Authors:  Tohru Kobayashi; Yoshinari Inoue; Kazuo Takeuchi; Yasunori Okada; Kazushi Tamura; Takeshi Tomomasa; Tomio Kobayashi; Akihiro Morikawa
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

2.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors:  Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

3.  Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease.

Authors:  Cedric Manlhiot; Kyle Millar; Fraser Golding; Brian W McCrindle
Journal:  Pediatr Cardiol       Date:  2009-12-19       Impact factor: 1.655

4.  Platelet count and erythrocyte sedimentation rate are good predictors of Kawasaki disease: ROC analysis.

Authors:  Song Xiu-Yu; Huang Jia-Yu; Hong Qiang; Dai Shu-Hui
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

5.  Acute-phase reactants and a supplemental diagnostic aid for Kawasaki disease.

Authors:  Ming-Yii Huang; Monesha Gupta-Malhotra; Joh-Jong Huang; Fei-Kai Syu; Teh-Yang Huang
Journal:  Pediatr Cardiol       Date:  2010-10-19       Impact factor: 1.655

6.  Resistance to intravenous immunoglobulin in children with Kawasaki disease.

Authors:  Adriana H Tremoulet; Brookie M Best; Sungchan Song; Susan Wang; Elena Corinaldesi; Julia R Eichenfield; Danielle D Martin; Jane W Newburger; Jane C Burns
Journal:  J Pediatr       Date:  2008-03-04       Impact factor: 4.406

7.  Risk factors for nonresponse to therapy in Kawasaki disease.

Authors:  Negar Ashouri; Masato Takahashi; Frederick Dorey; Wilbert Mason
Journal:  J Pediatr       Date:  2008-05-16       Impact factor: 4.406

8.  Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age.

Authors:  DooIl Song; Yunku Yeo; KeeSoo Ha; GiYoung Jang; JungHwa Lee; KwangChul Lee; ChangSung Son; JooWon Lee
Journal:  Eur J Pediatr       Date:  2009-01-22       Impact factor: 3.183

Review 9.  [Immunological aspects of Kawasaki disease].

Authors:  Jun Abe
Journal:  Nihon Rinsho       Date:  2008-02

10.  Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease.

Authors:  Elizabeth S Yellen; Kimberlee Gauvreau; Masato Takahashi; Jane C Burns; Stanford Shulman; Annette L Baker; Nancy Innocentini; Chiara Zambetti; Joan M Pancheri; Adam Ostrow; Jeffrey R Frazer; Robert P Sundel; David R Fulton; Jane W Newburger
Journal:  Pediatrics       Date:  2010-01-25       Impact factor: 7.124

View more
  33 in total

1.  Hepatic dysfunction secondary to Kawasaki disease: characteristics, etiology and predictive role in coronary artery abnormalities.

Authors:  Goshgar Mammadov; Hui Hui Liu; Wei Xia Chen; Guo Zhen Fan; Rui Xue Li; Fei Fei Liu; Sama Samadli; Jing Jing Wang; Yang Fang Wu; Huang Huang Luo; Dong Dong Zhang; Wei Wei; Peng Hu
Journal:  Clin Exp Med       Date:  2019-11-16       Impact factor: 3.984

2.  Serum alanine aminotransferase level and intravenous immunoglobulin resistance in patients with kawasaki disease.

Authors:  Hiroya Masuda; Ryusuke Ae; Taka-Aki Koshimizu; Koki Kosami; Nobuko Makino; Yuri Matsubara; Teppei Sasahara; Yosikazu Nakamura
Journal:  Clin Rheumatol       Date:  2022-07-07       Impact factor: 3.650

3.  Case of adult-onset Kawasaki disease and multisystem inflammatory syndrome following SARS-CoV-2 vaccination.

Authors:  Christopher R Showers; Jaslyn M Maurer; Doreen Khakshour; Mohit Shukla
Journal:  BMJ Case Rep       Date:  2022-07-04

4.  A Classification Tool for Differentiation of Kawasaki Disease from Other Febrile Illnesses.

Authors:  Shiying Hao; Bo Jin; Zhou Tan; Zhen Li; Jun Ji; Guang Hu; Yue Wang; Xiaohong Deng; John T Kanegaye; Adriana H Tremoulet; Jane C Burns; Harvey J Cohen; Xuefeng B Ling
Journal:  J Pediatr       Date:  2016-06-22       Impact factor: 4.406

5.  Psoriasiform eruptions during Kawasaki disease (KD): A distinct phenotype.

Authors:  Ellen S Haddock; Antoanella Calame; Chisato Shimizu; Adriana H Tremoulet; Jane C Burns; Wynnis L Tom
Journal:  J Am Acad Dermatol       Date:  2016-03-04       Impact factor: 11.527

6.  Changes in Hemoglobin Concentrations Post-immunoglobulin Therapy in Patients with Kawasaki Disease: A Population-Based Study Using a Claims Database in Japan.

Authors:  Masato Takeuchi; Shuichi Ito; Masaki Nakamura; Koji Kawakami
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

7.  Prediction of intravenous immunoglobulin resistance in patients with Kawasaki disease according to the duration of illness prior to treatment.

Authors:  Kee-Soo Ha; JungHwa Lee; Kwang Chul Lee
Journal:  Eur J Pediatr       Date:  2019-11-12       Impact factor: 3.183

8.  Atypically Protracted Course of Liver Involvement in Kawasaki Disease. Case Report and Literature Review.

Authors:  Pamela Paglia; Lucia Nazzaro; Anna Giulia Elena De Anseris; Milena Lettieri; Rossella Colantuono; Maria Chiara Rocco; Maria Anna Siano; Nicola Biffaro; Pietro Vajro
Journal:  Pediatr Rep       Date:  2021-07-01

9.  Kawasaki Disease Patient Stratification and Pathway Analysis Based on Host Transcriptomic and Proteomic Profiles.

Authors:  Heather Jackson; Stephanie Menikou; Shea Hamilton; Andrew McArdle; Chisato Shimizu; Rachel Galassini; Honglei Huang; Jihoon Kim; Adriana Tremoulet; Adam Thorne; Roman Fischer; Marien I de Jonge; Taco Kuijpers; Victoria Wright; Jane C Burns; Climent Casals-Pascual; Jethro Herberg; Mike Levin; Myrsini Kaforou
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

10.  Differential expression of miR-145 in children with Kawasaki disease.

Authors:  Chisato Shimizu; Jihoon Kim; Petra Stepanowsky; Christine Trinh; Hubert D Lau; Johnny C Akers; Clark Chen; John T Kanegaye; Adriana Tremoulet; Lucila Ohno-Machado; Jane C Burns
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.